Access

News


Nature Medicine 12, 983 (2006)
Published online: 30 August 2006 | doi:10.1038/nm0906-983a

Drug companies accused of stalling tailored therapies

Gunjan Sinha1

  1. Berlin


Companies are reluctant to limit their market share, report says.


Therapies tailored for people's distinct genetic makeup have for years been touted as the next big thing in drug development. But if those drugs have yet to materialize, it may be because drug companies don't want them to.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Nanoelectronics The strain of it all

Nature Nanotechnology News and Views (01 Jul 2008)